Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Uncategorized

Axcella Health Q1 EPS $(0.40) Beats $(0.42) Estimate

Axcella Health (NASDAQ:AXLA) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.42) by 4.76 percent. This is a 38.46 percent increase over losses of $(0.65) per share from the
byBill Haddad
May 6, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0

Axcella Health (NASDAQ:AXLA) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.42) by 4.76 percent. This is a 38.46 percent increase over losses of $(0.65) per share from the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Matinas BioPharma Announces Interim Data From The Phase 2 EnACT Trial Of MAT2203 For The Treatment Of Cryptococcal Meningitis, Exceeding Primary Endpoint Threshold; Patient Survival In All-Oral Cohort 4 Regimen Currently 90%

By Benzinga Newsdesk
Today, 8:03 AM
Two-week survival in Cohort 4 (all-oral regimen) was 95% in 40 patients receiving MAT2203     Mean Early Fungicidal Activity (EFA) of the rate of yeast clearance in cerebrospinal fluid exceeded

MTNB